Redhill Biopharma (STU:2RH0) Long-Term Capital Lease Obligation : €0.92 Mil (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma Long-Term Capital Lease Obligation?

Redhill Biopharma's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.92 Mil.

Redhill Biopharma's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (€6.08 Mil) to Mar. 2023 (€5.62 Mil) and declined from Mar. 2023 (€5.62 Mil) to Jun. 2023 (€0.92 Mil).

Redhill Biopharma's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€2.28 Mil) to Dec. 2022 (€6.08 Mil) but then declined from Dec. 2022 (€6.08 Mil) to Dec. 2023 (€0.42 Mil).

Redhill Biopharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Redhill Biopharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Long-Term Capital Lease Obligation Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.68

3.13

2.28

6.08

0.42

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															6.07	6.08	5.62	0.92	0.42

Redhill Biopharma (STU:2RH0) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Redhill Biopharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (STU:2RH0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH0) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

RDHL:USA 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Redhill Biopharma (STU:2RH0) Headlines

No Headlines